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ABSTRACT
Anxiety disorders (ADs) are disabling chronic disorders with exaggerated behavioral
response to threats. This study was aimed at testing the hypothesis that ADs may
be associated with reduced neurotrophic activity, particularly of Brain-derived neu-
rotrophic factor (BDNF), and determining possible effects of genetics on serum
BDNF concentrations. In 672 adult subjects from six isolated villages in North-
Eastern Italy with high inbreeding, we determined serum BDNF levels and identified
subjects with different ADs subtypes such as Social and Specific Phobias (PHSOC,
PHSP), Generalized Anxiety Disorder (GAD), and Panic Disorder (PAD). Analysis
of the population as a whole or individual village showed no significant correlation
between serum BDNF levels and Val66Met polymorphism and no association with
anxiety levels. Stratification of subjects highlighted a significant decrease in serum
BDNF in females with GAD and males with PHSP. This study indicates low heri-
tability and absence of any impact of the Val66Met polymorphism on circulating
concentrations of BDNF. Our results show that BDNF is not a general biomarker
of anxiety but serum BDNF levels correlate in a gender-specific manner with ADs
subtypes.
Subjects Genomics, Neuroscience, Global Health, Psychiatry and Psychology, Medical Genetics
Keywords Neurotrophins, Brain-derived neurotrophic factor, Serum biomarkers, Val66Met
polymorphism, Genome wide analysis, Anxiety, Sex factors, Generalized Anxiety Disorder,
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INTRODUCTION
Anxiety disorders (ADs) are disabling medical disorders affecting 6% of men and 13%
of women in the USA and 21% of the general population in Italy and France (US Census
Bureau, 2005; Alonso et al., 2004; Kessler et al., 2005a; Kessler et al., 2005b; Leray et al., 2011).
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ADs frequently occur early in life, have a chronic course and adversely affect the prognosis
of other medical illnesses (Kessler et al., 2005a; Van Noorden et al., 2012). ADs comprise
a collection of syndromes characterized by exaggerated fear responses to perceived
threats. Such threats extend to a wide range of situations in Generalized Anxiety Disorder
(GAD), and to specific ones, such as social evaluation in Social Phobia (PHSOC). ADs
commonly occur along with other mental or physical illnesses, including mood disorders
and alcohol or substance abuse, which may mask anxiety symptoms or make them worse
(Yu et al., 2013).
A current hypothesis is that ADs, in analogy with mood disorders, may be associated
with altered neurotrophic activity (Chen et al., 2006; Duman & Monteggia, 2006;
Hashimoto, 2010; Tsai, 2003). Accumulating evidence suggests the neurotrophin Brain
Derived Neurotrophic Factor (BDNF) is reduced in mood disorders (Duman&Monteggia,
2006; Tsai, 2003). Increased BDNF expression in the forebrain is at the base of the
antidepressant effect of many drugs and physical exercise acting through neurotrophic
enhancement of neuronal stem cells survival and stimulation of network connectivity
(Baj et al., 2012). In transgenic mice, overexpression of BDNF has a facilitating effect on
anxiety-like behaviour possibly due to increased spine density in amygdale (Govindarajan
et al., 2006). In another study in which anxiety-related personality traits were correlated
with BDNF polymorphism Val66Met, higher levels of trait anxiety were found in subjects
bearing the Val/Val BDNF allele compared to Val/Met and Met/Met genotypes having
reduced BDNF availability and secretion at synapses (Chen et al., 2006).
Interestingly, BDNF can be found not only in brain but also in peripheral tissues,
including blood. The opportunity to detect BDNF in serum has important clinical im-
plications because it provides the possibility to evaluate brain functions avoiding invasive
methods (Carlino et al., 2011; Elfving, Plougmann&Wegener, 2010; Trajkovska et al., 2007).
Accordingly, several studies focused on BDNF levels in blood as potential biomarker for
major depression disorder (MDD) and reported lower BDNF blood level in both serum
and plasma of drug-free patients compared to healthy controls (Bocchio-Chiavetto et al.,
2010; Karege et al., 2005; Lee & Kim, 2008; Sen, Duman & Sanacora, 2008; Shimizu et al.,
2003). In contrast, few studies were conducted to explore serum BDNF as a biomarker
in patients with anxiety disorders. In particular, reduced serum levels of BDNF have
been found in patients with panic disorders but no alterations were found for other ADs
(Kobayashi et al., 2005; Strohle et al., 2010). A study reported a weak association between
reduced serum BDNF and anxiety, but only in females (Molendijk et al., 2011). The aim
of the present research was to explore whether BDNF may represent a biomarker of ADs
by comparing serum BDNF levels among adult patients with different subtypes of ADs
which were Generalized Anxiety Disorder (GAD), Specific Phobia (PHSP), Panic Attack
Disorder (PAD), Social Phobia (PHSOC) and healthy donors, in a large population sample
(n= 672 subjects). Moreover, we estimated the heritability (the proportion of variance due
to genetic factors) of the blood levels of BDNF and performed an association analysis to
check for the association between rs6265 (responsible for the Val66Met polymorphism)
and BDNF levels. For both analysis we used already available whole genome genotyping
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data on the adult population of the Genetic Park (GP) from the Region “Friuli-Venezia
Giulia” consisting of 6 isolated villages in North–Eastern Italy, characterized by reduced
genetic variability (Esko et al., 2013).
MATERIALS & METHODS
Study population
The present study sample (672 subjects) was drawn from a large population of adults
investigated in the study “Genetic Park of Friuli Venezia Giulia (GP—Friuli Venezia
Giulia). This project was launched in Spring 2009 and involved, on a voluntary basis,
inhabitants of the “six geographical isolates” of Friuli Venezia Giulia, (i.e., Sauris,
Erto/Casso, San Martino, Illegio, Clauzetto, Resia). The aim of GP was to analyze the
environmental and genetic factors implicated in the pathogenesis of several diseases such
as mood disorders, deafness, osteoporosis and diabetes. The geographic isolates met the
criteria defining “genetic isolates” as separate geographical location with high endogamy
rate, language barrier, few surnames, few founders, low emigration and immigration rates.
The study was approved by the Ethics Committee of the IRCCS-Burlo Garofolo of Trieste.
Participants were informed about the study and those who provided a written consent were
included, according to the recommendations of the declaration of Helsinki and the Italian
DL no 675 of the 31-12-1996. All participants received a structured diagnostic interview
using the Composite International Diagnostic Interview (CIDI) in order to assess
current and lifetime DSM-IV-TR diagnoses. A total of 252 subjects fulfilled DSM-IV-TR
criteria for the diagnosis of ADs. Exclusion criteria were: diagnosis of substance abuse,
neurodegenerative disease, major depression, schizophrenia or bipolar depression.
BDNF assessment in GP—Friuli Venezia Giulia
Blood was collected from all 672 participants between 7:30 and 11:30 AM and immediately
transferred to laboratory sites for serum preparation or DNA extraction. Upon collection,
blood samples were split in two aliquots, one in tubes with anti-coagulant for DNA
analysis and the other in normal tubes for clotting and isolation of the serum samples.
During transfer from the villages to the laboratory site, blood samples for DNA extraction
were conserved at −30 ◦C, while samples for serum collection were at +4 ◦C. After
centrifugation at 2.000 g for 10 min, serum samples were stored at −80 ◦C and BDNF
measurement was performed in duplicate using the Emax Immuno assay System
(Promega) according to manufacturer and expressed in ng/mL. Samples were not acidified
before testing. The reaction was stopped 10–15 min later with 1M HCl solution, and the
absorbance was immediately measured at 450 nm (Promega Glomax Multi Detection
System). BDNF concentrations were determined from the regression line for the BDNF
standard ranging from 7.8 to 500 pg/ml BDNF.
Psychiatric assessment
The presence and severity of symptoms of anxiety were assessed using a composite psycho-
metric battery consisting of: (1) the Structure Clinical interview for DSM-IV-TR (SCID–I);
(2) the 14-item Hamilton Anxiety Rating Scale (HAM-A). Battery tests were administered
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Table 1 Baseline socio-demographic characteristics of the study sample.
Healthy donors AD p-value
N of subjects per group/total sample 420/672 252/672 –
Male/female 219/201 71/181 –
Age median value 47 48
Range 18–76 19–73
0.548
Serum BDNF median ng/ml 27.58 25.62 Total subject
25%–75% percentile 18.46–33.85 17.79–32.54 0.060
Male/female
Range of detection 3.33–66.85 3.10–63.78 0.225/0.067
Notes.
AD, anxiety disorders; SD, standard deviation.
by a neuropsychiatrist qualified and experienced in administering these interviews (D.C.).
Each interview was lasting approximately 60 min. Twenty percent of diagnostic interviews
were reviewed by a second neuropsychiatrist to confirm reliability of diagnostic categories.
Genotyping
DNA was extracted from all 672 blood samples according to the method described in
Esko et al., 2013. All DNA samples were genotyped with ILLUMINA arrays (ILLUMINA
HumanCNV370-Quad Beadchip) using standard protocols. After genotyping, all the
samples with a call rate <0.95, MAF <0.05 and markers with call-rate <0.95 or not in
Hardy–Weinberg equilibrium were removed.
Statistical analysis
All data were analyzed with R v.3.1.0. Variables’ distribution was tested for normality.
Differences in BDNF serum concentrations between the villages were determined by
one/two-way analysis of variance (ANOVA). Linear regression analysis was performed
to explore the relationship between serum BDNF levels and HAM-A scores in GAD,
PHSP, PAD, PHSOC. Mann–Whitney U test 1 tail was used to explore whether there were
different serum BDNF levels among control and patient groups in all villages. We chose the
1 tail Mann–Whitney U test because, according to previous studies, only decreased BDNF
levels are expected to be linked to mood disorders and pathological types of anxiety. The
heritability of BDNF levels was estimated using the restricted maximum likelihood analysis
implemented in GCTA (Yang et al., 2011) and association analysis corrected for kinship was
performed with GenABEL v.1.8. (Aulchenko et al., 2007).
RESULTS
Serum levels of BDNF, socio-demographics and anxiety
The population (n = 672) was stratified in healthy donors (HD) and patients with ADs.
Table 1 describes baseline socio-demographic characteristics of this sample. HD had a
median age of 47 years ranging from 18 to 76 years, whereas patients with ADs had a
median age of 48 years within a minimum of 19 to a maximum of 73 years. As serum BDNF
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Figure 1 Serum BDNF level in Healthy donors (n = 420) and Anxiety disorders Patients (n =
252). (A) BDNF values are not normally distributed. Mann–Whitney U Test 1-tail, revealed no significant
statistical difference between the two groups (p = 0.060). (B) Serum BDNF level in male and female
groups; n, number of subjects [healthy donors, patients]; male [219, 71], female [201, 181].
levels were not normally distributed, Mann–Whitney U test was used to compare median
values among the different groups. No significant difference in serum BDNF levels was
found between HD and AD groups (p = 0.06 MW-U Test; Fig. 1A). Indeed, in the HD
group the median BDNF value was 27.58 ng/ml, ranging from 3.33 ng/ml to 66.85 ng/ml,
and the AD group showed a quite similar median BDNF value (25.62 ng/ml, ranging from
3.10 ng/ml to 63.78 ng/ml) (Table 1). To determine whether there was any significant
difference related to gender, BDNF levels were compared in males and females in both HD
and AD groups (Fig. 1B). Mann–Whitney U test comparison between HD and AD males
showed no significant difference in BDNF levels (p= 0.225); and no significant difference
was found in female subjects between the two study groups (p= 0.067).
Carlino et al. (2015), PeerJ, DOI 10.7717/peerj.1252 5/16
Figure 2 Serum BDNF levels in six villages of the Genetic Park of Friuli Venezia Giulia; n, number
of subjects [healthy controls, patients]. (A) Clauzetto [69, 54], (B) Erto [27, 18], (C) Illegio [75, 50],
(D) Resia [139, 49], (E) San Martino [73, 38], (F) Sauris [40, 43]. A comparison Mann–Whitney U Test
1-tail shows no difference among the control and patient groups in all villages.
Heritability and association analysis
As previously reported by Esko et al., 2013, the population sample analyzed showed a high
degree of inbreeding and/or founder effects. The presence of high inbreeding may result in
a different incidence of specific disorders with respect to the outbred population and may
highlight the presence of single genetic polymorphisms with high impact on serum BDNF
levels. To investigate the effect of heritability on ADs incidence and serum BDNF levels,
we carried out an analysis of serum BDNF levels in the six villages of GP, considering the
gender. The analysis of the six isolated villages showed no significant difference among the
median value of healthy donors and ADs groups (Mann–Whitney U test 1-tail; Clauzetto
p= 0.488, Erto p= 0.482, Illegio p= 0.056, Resia p= 0.254, San Martino p= 0.436, Sauris
p= 0.137) (Fig. 2).
In order to check for a possible contribution of genetics to the basal BDNF levels in
the serum, we use the software GCTA. The result is that only 20% of the trait depends
from genetic factors (V(G)/Vp= 0.203262). We also tried to calculate the contribution of
every single chromosome to the trait in order to check for a major locus, but the results are
not reliable due to the small sample size. After heritability estimation, we used genotypes
data to perform an association analysis between BDNF levels and rs6265 polymorphism
controlling for relationship between samples and using an additive model. The availability
of whole genome genotyping data allowed us to conduct an association analysis corrected
for genomic kinship, avoiding any stratification bias potentially correlated with the use of
related samples. Association analysis using age, sex and village as covariate, was not able
to find an association with rs6265, the most studied polymorphism of BDNF (p-value of
0.26). In addition, the possible effect of the SNP rs6265 (Val66Met) was investigated in
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Figure 3 Serum BDNF in different diagnostic categories of Anxiety Disorder. (A) Box Plot Graph
showing the distribution of serum BDNF levels between different diagnostic categories of anxiety
disorders. (B–D) Linear regression analysis of serum BDNF levels and severity of disease in 3 different
categories of anxiety disorders measured with HAM-A (Hamilton Anxiety Rating Scale).
relation to BDNF levels and presence of anxiety disorders. Regression analysis with village
reveal that this SNP has no effect on blood level of BDNF or that the effect is too small to be
detected.
Serum levels of BDNF in anxiety disorders subtypes
We compared serum BDNF levels among patients with different ADs. Figure 3A shows
serum BDNF levels distribution in HD and the different AD diagnostic categories
including GAD (n = 91), PHSP (n = 95), PAD (n = 37), and PHSOC (n = 20). No
significant difference was found in serum BDNF levels for GAD Vs HD (p = 0.051);
PHSP Vs HD (p = 0.114); PAD Vs HD (p = 0.376); or PHSOC Vs HD (p = 0.913;
Mann–Whitney U test 2 tail). OCD was not considered because of the low number of
patients affected in the population investigated. In all forms of ADs, serum BDNF levels
resulted independent from the severity of disease (GAD p = 0.529; PHSP p = 0.066; PAD
p= 0.945, linear regression analysis Figs. 3B–3D).
Finally, serum BDNF levels were compared separately in males and females from
the healthy donor group versus each ADs category. Comparison showed a statistically
significant reduction of serum BDNF level in GAD female subjects with respect to female
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Figure 4 Analysis of BDNF levels gender differences in Generalized Anxiety Disorders and Specific
Phobia. (A) Serum BDNF level in male and female groups affected by Generalized Anxiety Disorder;
n, number of subjects [healthy donors, patients]; male [219, 28], female [201, 63]. Comparison using
Mann–Whitney U Test 1-tail shows significant statistical difference in serum BDNF level between the
two groups in female subjects (∗, p= 0.025). (B) Serum BDNF level in male and female groups affected
by Specific Phobia; male [219, 15], female [201, 82]. Comparison Mann–Whitney U Test 1-tail shows
significant statistical difference in serum BDNF level between the two groups in male subjects (∗, p =
0.018). Abbreviation: HD, Healthy Donors; GAD, Generalized Anxiety Disorders; PHSP, Specific Phobia.
HD (Fig. 4A; p = 0.025, Mann–Whitney U test 1 tail) but not in males. In contrast,
in males affected by PHSP there was a significant reduction in serum BDNF levels in
comparison to healthy donors, but not in females (Fig. 4B; male [219, 15] p = 0.018,
female [201, 63]; Mann–Whitney U test 1 tail). No significant gender difference was found
for patients with PAD and PHSOC.
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DISCUSSION
In this study, we tested the hypothesis that serum BDNF levels could be a potential
biomarker for the different subtypes of ADs. Analysis of the population as a whole or
single village excluded any correlation between serum BDNF levels and ADs as a whole or
as single diagnostic category. No correlation between BDNF levels and severity of anxiety
symptoms was found. However, considering the high level of hidden substructure of the
populations, when patients were stratified for both gender and disorder subtype we found
a significant decrease in serum levels of BDNF in GAD females. Genome wide analysis of
the population as a whole or individual village excluded significant correlations between
serum BDNF levels and the Val66Met polymorphism.
Measurement of circulating BDNF is considered of great interest as a possible biomarker
of psychiatric and neurodegenerative diseases. However, the origin of circulating BDNF is
currently a matter of discussion because in humans and in rodents, BDNF is produced by
various body tissues such as smooth muscle cells of blood vessels, skeletal muscles, kidney,
liver and brain (Aid et al., 2007; Pruunsild et al., 2007). In blood, BDNF is produced by
lymphocytes but not by megakaryocites, however, it is taken up by platelets that function as
storage and release system (Karege et al., 2005). The current focus of the debate is whether
circulating BDNF levels reflect or not the brain levels of this neurotrophin. Radiolabeled
BDNF injected in the jugular vein or in the brain ventricle readily crosses the blood–brain
barrier in both directions (Pan et al., 1998) In addition, it has been shown that physical
exercise induces an increase of serum BDNF levels which is contributed by 70% from
the brain (Rasmussen et al., 2009). Thus, measurement of serum levels of BDNF may
provide information on brain diseases and blood samples may be drawn from living
subjects to monitor disease progression or treatment efficacy. It has been proposed that
socio-demographics variables such as age may affect quantification of BDNF in serum.
However, controversial data have been reported on the relationship between serum BDNF
and age. Ziegenhorn et al., 2007 reported a weak age-associated decrease in serum BDNF
in a group of elderly above 70 years of age while a recent large population study reported
that BDNF levels decline with age in women, whereas in men remain stable (Bus et al.,
2012). Other studies found no correlation between age and BDNF in serum or whole blood
(Bus et al., 2011; Lommatzsch et al., 2005; Trajkovska et al., 2007). Another confirmation
of these findings comes from animal studies showing that brain BDNF concentration did
not change with age (Webster et al., 2002). In the sample analyzed in this study there was no
effect of age on serum BDNF levels.
A major outcome of this study is that we found no genetic effects or on serum levels of
BDNF and frequency of ADs, as evidenced by a little heritability of serum BDNF levels and
no significant association of the Val66Met polymorphism in genetically isolated, highly in-
bred populations. These populations were chosen because high inbreeding can increase the
frequency of rare variants with high impact on the phenotype and, thanks to the linkage
disequilibrium, these variants can be detected analyzing common variants in the same hap-
loblock with standard arrays. Complex traits are characterized by important environmen-
tal and polygenic contributions. Isolated populations which are characterized by a reduced
variability in both these factors, can facilitate the identification of both the genetic and
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environmental component because: (a) there is a reduction for the confounder effect of the
environment; (b) the relatedness reduces the genetic differences between case and controls
improving a lot the power to detect a true association. For this reason isolated populations
are often used to detect polymorphisms and environmental factors that contribute to
complex traits also in the general population, but that are easiest to detect in this context.
A heritability estimate for BDNF serum level was already reported by Terracciano et
al. (2013) who conducted a genome-wide analysis based on data from a larger samples
(ca. 1,600 subjects) and derived an estimate of ca 50%. The same paper also conducted a
meta-analysis of thirteen studies (for a total of ca. 4,700 samples) that already investigated
the association between Val66Met and serum BDNF level, similarly resulting in no
significant association with rs6265. In a further study on a genetically isolated population,
the same authors also conducted a SNP-by-SNP GWAS finding a number of suggestive
signals, although all below Bonferroni threshold, with some of them pointing for a role of
TrkC in regulation BDNF expression (Terracciano et al., 2013).
Every GWA study must face the problem of multiple testing due to the enormous num-
ber of independent test required. For this reason the p-value required for an association at
genome level is <5∗10−8. For complex traits in which every genetic variant gives a modest
contribution to the phenotype, this level of significance can be achieved only analyzing a
large number of samples (as in Terracciano et al., 2013). Our sample size is relatively small
for a successful GWA analysis, so we preferred to test the validity of an association with a
specific genetic variant (i.e., the rs6265 SNP) rather than test all the 370 k variants in the
array. However, we used all the genomic data only to perform the correction for the related-
ness between samples (using the genomic kinship) and heritability. Both these parameters
require whole genome data to be correctly calculated. Our data indicate a 20% heritability
which, due to the relatively small population sample of this study did not allow us to
identify any significant locus which can affect serum BDNF levels. In a previous study, on
a large sample of 6157 subjects, the estimated heritability for serum CRP level is between
25–40%, and 18 genome-wide significant loci were identified with evidence of replication
for eight of them (Dehghan et al., 2011). The poor heritability indicates that there isn’t a
major locus with high impact on BDNF levels. It is likely that BDNF levels is a multifacto-
rial trait with several loci involved, each of them with modest impact on the phenotype.
Our results are in agreement with a recent study by Molendijk and colleagues (2011)
who reported no overall differences for serum BDNF levels between healthy subjects and
patients with ADs. Other studies reported lower BDNF levels in PAD patients compared to
HDs (Strohle et al., 2010), or no differences, although the PAD patients who were poor re-
sponders to a cognitive behavioural therapy showed lower BDNF serum levels (Kobayashi
et al., 2005). Taken together, our results and those of previous studies support the idea that
reduced BDNF levels cannot represent per se a pathophysiological cause of ADs. The ab-
sence of significant differences in serum BDNF levels between anxious subjects and healthy
donors indicate that BDNF is not a general biomarker of anxiety. On the other hand in
rodents, overexpression of the TrkB high affinity receptor for BDNF, leads to increased anx-
iety indicating that BDNF signalling is associated with anxiety (Koponen et al., 2004). How-
ever, since TrkB is an integral membrane receptor, its levels are not measurable in serum.
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In this study besides BDNF, we did not investigated the other members of the
neurotrophin family which also includes Nerve Growth Factor (NGF), Neurotrophin-3
(NT-3) and Neurotrophin-4/5 (NT-4/5) because the available data indicate that they are
not useful as biomarkers of anxiety. Indeed, although it was previously shown that NGF
levels raise in the serum of soldiers in proximity to their first parachute jumps, in patients
affected by generalized anxiety disorder (GAD), NGF levels were not different from
controls (Aloe et al., 1994; Jockers-Scherubl et al., 2007). Similarly, in the serum of depressed
adolescents or in the brain of maternally separated mice, two conditions including high
anxiety levels, NT-3 levels are not different from controls while no information is available
yet on NT-4/5 (Pallavi et al., 2013; Yee et al., 2007).
Concerning gender differences, our findings are in agreement with studies which
found no gender difference regarding BDNF serum level (Lang, Hellweg & Gallinat, 2004;
Ziegenhorn et al., 2007). However, other studies reported that BDNF in whole blood or
plasma was higher in women compared to men (Lommatzsch et al., 2005; Trajkovska et
al., 2007). On the other hand, our findings strongly support a specific contribution of low
serum levels of BDNF to vulnerability to GAD in females and PHSP in males, which is
partially in agreement proposed hypothesis that serum BDNF is altered only in females
with multiple types of ADs (Molendijk et al., 2011). Although epidemiologic studies have
clearly shown that women are more likely than men to develop anxiety-related disorders,
the current evidence does not support that female sex can represent a vulnerability
factor of anxiety, per se. Indeed, it has been recently proposed that a second factor of
vulnerability should be taken into account: i.e., behavioural inhibition (Catuzzi & Beck,
2014). Behavioral inhibition (BI) is characterized by rapid acquisition of anxiogenic
stimuli-induced responses that are resistant to extinction and may be present in both
sexes. In this “two hit” model of anxiety vulnerability, females possessing a BI temperament
with resistant associations between a given stimulus and a behavioural response, will more
likely to develop an anxiety disorder (Catuzzi & Beck, 2014). Besides these considerations,
the reason for the gender-specific association of lowered BDNF levels with GAD in females
and PHSP in males is presently unknown and warrants future investigations.
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